Ligand Pharmaceuticals swings to Q3 net loss of $28.49 million from year-earlier profit
LGND•Ligand Pharmaceuticals reported a third-quarter net loss of $28.49 million, while adjusted earnings per diluted share fell 14% to $2.67 and adjusted total revenues and income rose 26% to $78.7 million, excluding prior-year Pelthos-related income. It raised 2026 adjusted earnings guidance to $9.50–$9.75 per diluted share.
1. Quarterly results and outlook
Ligand Pharmaceuticals reported a third-quarter net loss of $28.49 million, compared with a profit a year earlier. Adjusted earnings per diluted share fell 14% year over year to $2.67, while adjusted total revenues and income rose 26% to $78.7 million, excluding prior-year Pelthos-related income. The completed XOMA Royalty acquisition more than doubled the portfolio to over 200 assets, and the company raised its 2026 adjusted earnings guidance to $9.50–$9.75 per diluted share from $9–$9.50.
